Skip to content 
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. more
| Time Frame | SNY | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -6.31% | 0.72% | -1.31% |
| 1-Month Return | 0.87% | 1.27% | 0.78% |
| 3-Month Return | -8.92% | 3.13% | 3.46% |
| 6-Month Return | -7.42% | 15.81% | 6.19% |
| 1-Year Return | -14.48% | 8.89% | 11.68% |
| 3-Year Return | -3.07% | 20.79% | 71.21% |
| 5-Year Return | -2.47% | 35.89% | 74.81% |
| 10-Year Return | 17.7% | 138.44% | 256.59% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 39.17B | 40.56B | 41.62B | 44.29B | 46.72B | [{"date":"2021-12-31","value":83.86,"profit":true},{"date":"2022-12-31","value":86.82,"profit":true},{"date":"2023-12-31","value":89.09,"profit":true},{"date":"2024-12-31","value":94.8,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 12.26B | 11.88B | 12.63B | 13.21B | 12.92B | [{"date":"2021-12-31","value":92.81,"profit":true},{"date":"2022-12-31","value":89.98,"profit":true},{"date":"2023-12-31","value":95.63,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":97.86,"profit":true}] |
| Gross Profit | 26.92B | 28.68B | 28.99B | 31.08B | 33.79B | [{"date":"2021-12-31","value":79.66,"profit":true},{"date":"2022-12-31","value":84.87,"profit":true},{"date":"2023-12-31","value":85.79,"profit":true},{"date":"2024-12-31","value":91.97,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 68.72% | 70.71% | 69.66% | 70.18% | 72.34% | [{"date":"2021-12-31","value":95,"profit":true},{"date":"2022-12-31","value":97.74,"profit":true},{"date":"2023-12-31","value":96.3,"profit":true},{"date":"2024-12-31","value":97.02,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 18.79B | 18.52B | 22.03B | 23.83B | 27.45B | [{"date":"2021-12-31","value":68.47,"profit":true},{"date":"2022-12-31","value":67.46,"profit":true},{"date":"2023-12-31","value":80.26,"profit":true},{"date":"2024-12-31","value":86.81,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 8.13B | 10.16B | 6.96B | 7.25B | 6.34B | [{"date":"2021-12-31","value":79.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.49,"profit":true},{"date":"2024-12-31","value":71.36,"profit":true},{"date":"2025-12-31","value":62.43,"profit":true}] |
| Total Non-Operating Income/Expense | (617.00M) | (404.00M) | (1.48B) | (1.05B) | - | [{"date":"2021-12-31","value":-61700000000,"profit":false},{"date":"2022-12-31","value":-40400000000,"profit":false},{"date":"2023-12-31","value":-148400000000,"profit":false},{"date":"2024-12-31","value":-105400000000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 7.84B | 9.99B | 6.12B | 6.76B | 6.02B | [{"date":"2021-12-31","value":78.43,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61.2,"profit":true},{"date":"2024-12-31","value":67.63,"profit":true},{"date":"2025-12-31","value":60.25,"profit":true}] |
| Income Taxes | 1.56B | 1.91B | 1.02B | 1.20B | 1.04B | [{"date":"2021-12-31","value":81.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.27,"profit":true},{"date":"2024-12-31","value":63.07,"profit":true},{"date":"2025-12-31","value":54.64,"profit":true}] |
| Income After Taxes | 6.28B | 8.08B | 5.10B | 5.55B | - | [{"date":"2021-12-31","value":77.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":63.07,"profit":true},{"date":"2024-12-31","value":68.71,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 6.28B | 6.83B | 5.44B | 5.55B | - | [{"date":"2021-12-31","value":91.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.56,"profit":true},{"date":"2024-12-31","value":81.28,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 6.22B | 8.37B | 5.40B | 5.56B | 7.81B | [{"date":"2021-12-31","value":74.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.51,"profit":true},{"date":"2024-12-31","value":66.42,"profit":true},{"date":"2025-12-31","value":93.33,"profit":true}] |
| EPS (Diluted) | 3.87 | 4.32 | 5.77 | 4.12 | 5.15 | [{"date":"2021-12-31","value":67.07,"profit":true},{"date":"2022-12-31","value":74.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":71.4,"profit":true},{"date":"2025-12-31","value":89.24,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| SNY | |
|---|---|
| Cash Ratio | 0.27 |
| Current Ratio | 1.09 |
| Quick Ratio | 0.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| SNY | |
|---|---|
| ROA (LTM) | 4.56% |
| ROE (LTM) | 6.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| SNY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.56 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| SNY | |
|---|---|
| Trailing PE | 19.17 |
| Forward PE | 9.22 |
| P/S (TTM) | 2.39 |
| P/B | 1.31 |
| Price/FCF | 70 |
| EV/R | 2.28 |
| EV/Ebitda | 12.50 |
| PEG | 0.69 |
Sanofi ADR (SNY) share price today is $46.14
Yes, Indians can buy shares of Sanofi ADR (SNY) on Vested. To buy
Yes, you can purchase fractional shares of Sanofi ADR (SNY) via the Vested app. You can start investing in Sanofi ADR (SNY) with a minimum investment of $1.
You can invest in shares of Sanofi ADR (SNY) via Vested in three simple steps:
The 52-week high price of Sanofi ADR (SNY) is $57.57. The 52-week low price of Sanofi ADR (SNY) is $44.62.
The price-to-earnings (P/E) ratio of Sanofi ADR (SNY) is 19.1708
The price-to-book (P/B) ratio of Sanofi ADR (SNY) is 1.31
The dividend yield of Sanofi ADR (SNY) is 8.76%
The market capitalization of Sanofi ADR (SNY) is $112.14B
The stock symbol (or ticker) of Sanofi ADR is SNY
Consider the share price of Sanofi ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Sanofi ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Sanofi ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Sanofi ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Sanofi ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Sanofi ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
